Male infertility is a clinical manifestation which concerns approximately 15 % of all couples in Europe. Male causes for infertility are found in 50% of involuntarily childless couples. For Germany this counts for a n...Male infertility is a clinical manifestation which concerns approximately 15 % of all couples in Europe. Male causes for infertility are found in 50% of involuntarily childless couples. For Germany this counts for a number of an equivalent of 50 000 men/year, No causal factor is found in 60%-75% of cases （idiopathic male infertility）. Nevertheless, reduced male fertility can be the result of congenital and acquired urogenital abnormalities, increased scrotal temperature （varicocele）, endocrine disturbances, genetic abnormalities and immunological factors. Furthermore, urogenital inflammations and infections play an important role. Indications for microbiological assessment include abnormal urine samples, urinary tract infections, prostatitis, epididymitis, orchitis, ejaculate infections and sexually transmitted diseases. In the following review, different infectious diseases of the male urogenital tract and their implications on fertility were reviewed.展开更多
Objective： To investigate treatment efficacy for persistent chlamydial infection in the urogenital tract. Methods： 207 patients with persistent chlamydial urogenital infection were treated with tetracycline,azithrom...Objective： To investigate treatment efficacy for persistent chlamydial infection in the urogenital tract. Methods： 207 patients with persistent chlamydial urogenital infection were treated with tetracycline,azithromycin, ofloxacin or a combination of these.Result： 47.92%-68.60% of patients with persistent chlamydial urogenital infection were cured depending on the drug used. Ofloxacin had better results than tetracycline and azithromycin.Conclusion： Many patients were resistant to treatment with tetracycline and azithromycin. Ofloxacin proved effective.展开更多
Both diabetes and fungal infections contribute significantly to the global disease burden,with increasing trends seen in most developed and developing countries during recent decades.This is reflected in urogenital in...Both diabetes and fungal infections contribute significantly to the global disease burden,with increasing trends seen in most developed and developing countries during recent decades.This is reflected in urogenital infections caused by Candida species that are becoming ever more pervasive in diabetic patients,particularly those that present with unsatisfactory glycemic control.In addition,a relatively new group of anti-hyperglycemic drugs,known as sodium glucose cotransporter 2 inhibitors,has been linked with an increased risk for colonization of the urogenital region with Candida spp.,which can subsequently lead to an infectious process.In this review paper,we have highlighted notable virulence factors of Candida species(with an emphasis on Candida albicans)and shown how the interplay of many pathophysiological factors can give rise to vulvovaginal candidiasis,potentially complicated with recurrences and dire pregnancy outcomes.We have also addressed an increased risk of candiduria and urinary tract infections caused by species of Candida in females and males with diabetes,further highlighting possible complications such as emphysematous cystitis as well as the risk for the development of balanitis and balanoposthitis in(primarily uncircumcised)males.With a steadily increasing global burden of diabetes,urogenital mycotic infections will undoubtedly become more prevalent in the future;hence,there is a need for an evidence-based approach from both clinical and public health perspectives.展开更多
Acquired resistance of mycoplasmas to antibiotics constitutes a major health problem in the world in general and in Africa in particular. Despite the diversity of kits marketed, several of them evaluating the sensitiv...Acquired resistance of mycoplasmas to antibiotics constitutes a major health problem in the world in general and in Africa in particular. Despite the diversity of kits marketed, several of them evaluating the sensitivity of mycoplasmas to antibiotics continue to present resistance, in this case, the Mycoplasma IST2. In order to overcome this resistance, a new kit (Mycoplasma IST3) has been developed in accordance with the new Clinical and Laboratory Standard Institute (CLSI) recommendations. The objective of the study was to determine the resistance profile of urogenital Mycoplasmas to antibiotics using this new kit and to highlight cases of co-infections in comparison with the Mycoplasma IST2. Over a period of four mo nths, one hundred and one (101) samples of urogenital secretions were collected (from sexually active men and women) and analyzed. Culture and antibiotic susceptibility testing were performed in a liquid medium using the Mycoplasma IST2 and Mycoplasma IST3 Tests according to the manufacturer’s recommendations. Among the different samples analyzed, we noted a mycoplasma positivity rate of 71.29% with a predominance of infection in women, i.e. 86.12% compared to men 13.88%. Ureaplasma spp was the most encountered germ with a rate of 62.50% followed by cases of co-infections at 33.33% (Uspp/Mh) and the least encountered was Mycoplasma hominis with a rate of 2.79%. We analyzed 25 samples, among which we had 4 co-infections, simultaneously using the two kits in the same patients. The distribution of cases between the two kits was equivalent. We noted a significant rate of resistance to erythromycin 100% using Mycoplasma IST2. However, no resistance was observed in erythromycin with Mycoplasma IST3. Mycoplasma IST2 also showed resistance to fluoroquinolones, which was not the case for Mycoplasma IST3 which did not show any resistance to fluoroquinolones. Both kits showed resistance to tetracycline. The antibiotic sensitivity test using the Mycoplasma IST3 revealed a high rate of resistance to tetracycline, i.e. 57.14% and 91.67% for Ureaplasma spp and Mycoplasma hominis respectively. Resistance rates to other antibiotics were less than 25%. This study was able to demonstrate that Mycoplasma IST3 constitutes a better therapeutic choice compared to its predecessor Mycoplasma IST2, because it eliminated the biggest shortcoming of its predecessor.展开更多
文摘Male infertility is a clinical manifestation which concerns approximately 15 % of all couples in Europe. Male causes for infertility are found in 50% of involuntarily childless couples. For Germany this counts for a number of an equivalent of 50 000 men/year, No causal factor is found in 60%-75% of cases （idiopathic male infertility）. Nevertheless, reduced male fertility can be the result of congenital and acquired urogenital abnormalities, increased scrotal temperature （varicocele）, endocrine disturbances, genetic abnormalities and immunological factors. Furthermore, urogenital inflammations and infections play an important role. Indications for microbiological assessment include abnormal urine samples, urinary tract infections, prostatitis, epididymitis, orchitis, ejaculate infections and sexually transmitted diseases. In the following review, different infectious diseases of the male urogenital tract and their implications on fertility were reviewed.
文摘Objective： To investigate treatment efficacy for persistent chlamydial infection in the urogenital tract. Methods： 207 patients with persistent chlamydial urogenital infection were treated with tetracycline,azithromycin, ofloxacin or a combination of these.Result： 47.92%-68.60% of patients with persistent chlamydial urogenital infection were cured depending on the drug used. Ofloxacin had better results than tetracycline and azithromycin.Conclusion： Many patients were resistant to treatment with tetracycline and azithromycin. Ofloxacin proved effective.
文摘Both diabetes and fungal infections contribute significantly to the global disease burden,with increasing trends seen in most developed and developing countries during recent decades.This is reflected in urogenital infections caused by Candida species that are becoming ever more pervasive in diabetic patients,particularly those that present with unsatisfactory glycemic control.In addition,a relatively new group of anti-hyperglycemic drugs,known as sodium glucose cotransporter 2 inhibitors,has been linked with an increased risk for colonization of the urogenital region with Candida spp.,which can subsequently lead to an infectious process.In this review paper,we have highlighted notable virulence factors of Candida species(with an emphasis on Candida albicans)and shown how the interplay of many pathophysiological factors can give rise to vulvovaginal candidiasis,potentially complicated with recurrences and dire pregnancy outcomes.We have also addressed an increased risk of candiduria and urinary tract infections caused by species of Candida in females and males with diabetes,further highlighting possible complications such as emphysematous cystitis as well as the risk for the development of balanitis and balanoposthitis in(primarily uncircumcised)males.With a steadily increasing global burden of diabetes,urogenital mycotic infections will undoubtedly become more prevalent in the future;hence,there is a need for an evidence-based approach from both clinical and public health perspectives.
文摘Acquired resistance of mycoplasmas to antibiotics constitutes a major health problem in the world in general and in Africa in particular. Despite the diversity of kits marketed, several of them evaluating the sensitivity of mycoplasmas to antibiotics continue to present resistance, in this case, the Mycoplasma IST2. In order to overcome this resistance, a new kit (Mycoplasma IST3) has been developed in accordance with the new Clinical and Laboratory Standard Institute (CLSI) recommendations. The objective of the study was to determine the resistance profile of urogenital Mycoplasmas to antibiotics using this new kit and to highlight cases of co-infections in comparison with the Mycoplasma IST2. Over a period of four mo nths, one hundred and one (101) samples of urogenital secretions were collected (from sexually active men and women) and analyzed. Culture and antibiotic susceptibility testing were performed in a liquid medium using the Mycoplasma IST2 and Mycoplasma IST3 Tests according to the manufacturer’s recommendations. Among the different samples analyzed, we noted a mycoplasma positivity rate of 71.29% with a predominance of infection in women, i.e. 86.12% compared to men 13.88%. Ureaplasma spp was the most encountered germ with a rate of 62.50% followed by cases of co-infections at 33.33% (Uspp/Mh) and the least encountered was Mycoplasma hominis with a rate of 2.79%. We analyzed 25 samples, among which we had 4 co-infections, simultaneously using the two kits in the same patients. The distribution of cases between the two kits was equivalent. We noted a significant rate of resistance to erythromycin 100% using Mycoplasma IST2. However, no resistance was observed in erythromycin with Mycoplasma IST3. Mycoplasma IST2 also showed resistance to fluoroquinolones, which was not the case for Mycoplasma IST3 which did not show any resistance to fluoroquinolones. Both kits showed resistance to tetracycline. The antibiotic sensitivity test using the Mycoplasma IST3 revealed a high rate of resistance to tetracycline, i.e. 57.14% and 91.67% for Ureaplasma spp and Mycoplasma hominis respectively. Resistance rates to other antibiotics were less than 25%. This study was able to demonstrate that Mycoplasma IST3 constitutes a better therapeutic choice compared to its predecessor Mycoplasma IST2, because it eliminated the biggest shortcoming of its predecessor.
